Is it true that rubicartin cured small cell lung cancer? How effective is it?

Lurbinectedin/Lurbinectedin is a new anti-cancer drug mainly used to treat small cell lung cancer (SCLC). Its efficacy has attracted much attention, but the statement "cure" needs to be treated with caution. Although rubicatin has shown significant efficacy in some patients, there is no guarantee that all patients will be completely cured.

The mechanism of action of Rubicatin is to interfere with the proliferation of cancer cells by inhibitingDNA transcription and repair. It was originally designed to solve the problem of drug resistance that may occur in patients with small cell lung cancer after receiving traditional chemotherapy. Patients with small cell lung cancer (SCLC) who have progressed after first-line therapy have few treatment options. A new treatment approach is represented by rubicatin, a synthetic derivative of trabectedin that works by inhibiting oncogenic transcription of tumor cells and promoting apoptosis. A phase II trial demonstrated the activity of rubicatin at a dose of 3.2 mg/m2 in patients with small cell lung cancer who had failed prior chemotherapy, with an effective rate of 35.2%, a median progression-free survival (mPFS) of 3.5 months, and a median overall survival (mOS) of 9.3 months. Common serious adverse events (Grade 3-4) were hematologic disorders, including anemia (9%), leukopenia (29%), neutropenia (46%), and thrombocytopenia (7%).

Rubicatin has shown modest efficacy in past studies, particularly in patients who have failed to respond to or relapsed with standard chemotherapy regimens. Some patients have experienced tumor shrinkage and prolonged survival after using rubicatin, which is a positive sign for patients seeking new treatment options.

In clinical application, rubicatin has relatively minor side effects. Common adverse reactions include fatigue, nausea, loss of appetite, blood system-related side effects, etc. When doctors use Rubicatin, they will carefully evaluate the patient's overall condition to develop the best treatment plan.